| December | November | October | September | August | July | June | May | April | March | February | January |
| Company Acquired | Acquired By Or Merged With | Date Announced | Date Completed | Value (M) | Terms/Details |
| Agritope Inc. (AGTO) | Exelixis Inc. (EXEL) | 9/10 | 12/8 | $31 | Agritope stockholders will receive about 1.7M shares of Exelixis stock |
| Bartels Inc. (unit of Intracel Corp.) | Trinity Biotech plc (Ireland; TRIB) | 12/18 | 12/18 | $9.3 | Trinity acquired the assets of Bartels for $9.3M, including $3.2M in Trinity stock |
| Biomatrix Inc. (NYSE:BXM) | Genzyme Tissue Repair and Genzyme Surgical Products | 3/00 | 12/19 | $611 | Merger will create Genzyme Biosurgery, a new division of Genzyme Corp. with its own new stock; combined market value as of 3/3 totaled $1.3 billion; Biomatrix shareholders will hold approximately 47% of the new company; Genzyme and BioMatrix shareholders approved the merger agreement in December |
| Cambridge NeuroScience Inc. (UK: OTC BB:CNSI) | CeNeS Pharmaceuticals (UK; LSE:CEN) | 5/23 | 12/21 | ND | CeNeS and Cambridge NeuroScience merged with CeNeS issuing 42.6M shares |
| CliniChem Development Inc. | BioChem Pharma Inc. (Canada; BCHE; TSE:BCH) | 10/26 | 12/18 | $32.9 | BioChem paid C$18.43 (US$12.129) per share for each CliniChem class A share for a total of US$32.9M |
| Coulter Pharmaceutical Inc. (CLTR) | Corixa Corp. (CRXA) | 10/16 | 12/22 | $570 | Corixa acquired Coulter for about $570M with an exchange ratio of 1.003 shares of Corixa for each share of Coulter |
| Fielding Pharmaceutical Co. | Novavax Inc. (AMEX:NOX) | 10/00 | 12/21 | $31.5 | Novavax completed its acquisition of Fielding, which will operate as a wholly owned subsidiary |
| GelTex Pharmaceuticals Inc. | Genzyme Corp. (GENZ) | 9/00 | 12/15 | $1B | Genzyme acquired GelTex issuing shareholders $22.59 in cash and 0.3818 of a share of Genzyme General, or $48.50 in cash, for each GelTex share |
| Immune Complex Corp. | Evax Technologies AG (Germany) | 12/18 | 12/18 | ND | Evax acquired Immune Complex and will change its name to Apovia AG; ICC will become Apovia Inc. |
| Kinetix Pharmaceuticals Inc. | Amgen Inc. (AMGN) | 10/00 | 12/15 | $170 | Amgen acquired Kinetix for $170M |
| Medicomp Inc. and Telemedical Procedures LLC | United Therapeutics Corp. (UTHR) | 12/28 | 12/28 | $11.6 | United Therapeutics paid $8M in cash and about 260,000 shares valued at about $3.6M |
| Megan Health Inc. | Avant Immunotherapeutics Inc. (AVAN) | 11/00 | 12/00 | $18 | Avant issued 1.9M shares to Megan's shareholders; upon completion, Avant will have 57M shares outstanding |
| Mitoscan Corp. | Harvard Bioscience Inc. (HBIO) | 12/28 | 12/28 | $0.3 | Harvard Bioscience acquired Mitoscan for up-front payments of $300,000, additional contingent payments and royalty payments based on sales |
| Moldyn Inc. | Structural Bioinformatics Inc. | 12/00 | 12/00 | ND | Structural Bioinformatics acquired Moldyn for an undisclosed amount |
| Mycota Biosciences Inc. (Canada) | Elitra Pharmaceuticals Inc. | 10/00 | 12/00 | $19.34 | Elitra completed its acquisition issuing 5.95M shares; Mycota will continue as a wholly owned subsidiary of Elitra |
| Company Acquired | Acquired By Or Merged With | Date Announced | Date Completed | Value (M) | Terms/Details |
| Aquila Biopharmaceuticals Inc. (AQLA) | Antigenics Inc. (AGEN) | 8/00 | 11/00 | $40 | Antigenics will issue about 2.5M shares of stock, and Aquila will operate as a wholly owned subsidiary of Antigenics |
| BioAlliance Inc. and Collaborative Smithfield Corp. | Dow Chemical Co. (NYSE:DOW) | 10/00 | 11/00 | ND | Dow acquired The Collaborative Group's Biotechnology Services Division, including all assets of the two companies |
| Biomune Systems Inc. (BIME) | Donlar Corp. | 8/00 | 11/00 | $5.8 | Donlar owns approximately 96% voting control of Biomune; the resulting company will be re-named Donlar Corp. |
| Cistron Biotechnology Inc. (OTC BB:CIST) | Celltech Group plc (UK; LSE:CCH; NYSE:CLL) | 3/00 | 11/00 | $18 | Cistron shareholders will receive about 0.0202 of a Celltech American depositary share in exchange for each outstanding Cistron share; Cistron will no longer be traded publicly |
| Crescendo Pharmaceuticals (CNDO) | ALZA Corp. (NYSE:AZA) | 10/00 | 11/00 | $100 | ALZA exercised its option to acquire all outstanding Class A Crescendo common stock in cash |
| CytoGenesis Inc. | BresaGen Ltd. (Australia; AMEX:BGN) | 8/00 | 11/00 | ND | BresaGen issued about 7M shares and 2M options |
| DNX Transgenic Sciences Inc. | Xenogen Corp. | 9/00 | 11/00 | ND | Xenogen issued 3.5M shares of stock in exchange for all outstanding shares of DNX |
| Dura Pharmaceuticals Inc.(DURA) | Elan Corp. plc (Ireland; NYSE:ELN) | 9/00 | 11/00 | $1.8B | Elan acquired each share of Dura for 0.6715 of an Elan ADS |
| Immgenics Inc. (Canada) | Abgenix Inc. (ABGX) | 9/00 | 11/00 | C$110 (US$77) | Abgenix exchanged US$77M of its stock for all of ImmGenics shares and options |
| Intracardia Inc. | Cardiogene AG (Germany) | 11/00 | 11/00 | ND | Cardiogene will change its name to Cardion AG and the corporate headquarters will be in Erkrath, Germany; new company will focus on heart disease and cell transplantation |
| IntraImmune Therapies Inc. | Abgenix Inc. (ABGX) | 11/00 | 11/00 | $9 | Abgenix acquired IntraImmune for $9M in cash |
| Oxford Asymmetry International plc (UK; LSE:OAI) | Evotec BioSystems AG (Germany; Neuer Markt:EVT) | 7/00 | 11/00 | $475 | OAI shareholders received 0.1287 Evotec shares for each OAI share held; the offer values OAI at 722 pence per share, a premium of approximately 46%; OAI shareholders will own about 31% of the merged company |
| Synthetic Genetics | Epoch Biosciences Inc. (EBIO) | 11/00 | 11/00 | $3.1 | Epoch acquired Synthetic Genetics from the Immune Complex Corp. for $3.1M in cash |
| Company Acquired | Acquired By Or Merged With | Date Announced | Date Completed | Value (M) | Terms/Details |
| Anesta Corp. (NSTA) | Cephalon Inc. (CEPH) | 7/00 | 10/00 | $444 | Cephalon issued 6.7M shares to acquire Anesta; Anesta is a wholly owned subsidiary of Cephalon |
| BioQuest Inc. (Pink Sheets:BQST) | Biokeys Inc. | ND | 10/00 | ND | BioQuest and Biokeys merged to become publicly traded Biokeys Pharmaceuticals Inc. (Pink Sheets:BKYS) in a tax-free merger of equals |
| GSLI Life Sciences Inc. (GSLI) | Packard BioScience Co. (PBSC) | 8/00 | 10/00 | $120 | Packard acquired GSLI Life Sciences, a division of GSI Lumonics Inc., including its bioinformatics software products, for $40M and approximately 4.6M shares of its common stock; the GSLI Life Sciences group will become a part of Packard BioChip Technologies LLC |
| HepaVec AG (Germany) | DeveloGen AG (Germany) | 5/00 | 10/00 | ND | The two companies merged to create a company focused on disease therapeutics based on developmental biology |
| Medeva Vaccines | PowderJect Pharmaceuticals plc (London, LS:PJP) | 8/00 | 10/00 | $79 | PowderJect acquired the Medeva vaccines business from Celltech Group plc for $30M in cash and $32M as a balance payment on sales of the Fluvirin flu vaccine; the business will be merged into PowderJect's wholly owned subsidiary, PowderJect Vaccines |
| Neomorphic Inc. | Affymetrix Inc. (AFFX) | 10/00 | 10/00 | $70 | Affymetrix will integrate Neomorphic's genomic data with its expressed sequence tag information, issuing approximately 1.4M shares in exchange for all of Neomorphic's outstanding shares and options; in lieu of an increase in the aggregate number of Affymetrix shares issued, it has the option of paying cash in an aggregate amount not to exceed $20M |
| Quorum Sciences Inc. | Aurora Biosciences Corp. (ABSC) | ND | 10/00 | $3.8 | Aurora acquired Quorum Sciences for 81,287 shares of Aurora common stock |
| Talaria Therapeutics Inc. | Esperion Therapeutics Inc. (ESPR) | 10/00 | 10/00 | $7.2 | All outstanding shares of Talaria were exchanged for 813,000 shares of Esperion common stock; Esperion will make milestone payments to Talaria stockholders in addition to royalties on net sales of large unilamellar vesicles |
| TerraGen Discovery Inc. | Cubist Pharmaceuticals Inc. (CBST) | 8/00 | 10/00 | $29 | Cubist issued approximately $29M worth of stock (about 0.608M shares) to acquire TerraGen |
| Company Acquired | Acquired By Or Merged With | Date Announced | Date Completed | Value (M) | Terms/Details |
| Genovo Inc. | Targeted Genetics Corp. (TGEN) | 8/00 | 9/00 | $83.29 | Targeted Genetics exchanged $83.29M worth of stock, or 6.63M shares, for all outstanding shares of Genovo |
| Hybridon (DNA manufacturing unit) (OTC:HYBN) | Avecia Inc. | 9/00 | 9/00 | $15 | Avecia acquired the DNA manufacturing business of Hybridon, which will remain an independent company focused on oncology and immunotherapeutics |
| Life Technologies Inc. (LTEK) and Dexter Corp. (NYSE:DEX) | Invitrogen Corp. (IVGN) | 7/00 | 9/00 | $1.9B | Invitrogen acquired Life Technologies and Dexter for $1.9B in cash and stock; Dexter owned about 75% of Life Technologies; Invitrogen paid about $62.50 per share for Dexter, or $1.5B, and $60 per share for the Life shares not owned by Dexter, or $400M; the maximum cash portion for Dexter is $410M, and for Life, $105M |
| PathoGenesis Corp. (PGNS) | Chiron Corp. (CHIR) | 8/00 | 9/00 | $700 | Chiron acquired PathoGenesis for $700M in cash ($38.50 per share) |
| Principia Pharmaceutical Corp. | Human Genome Sciences Inc. (HGSI) | 9/00 | 9/00 | $120 | HGS exchanged $120M worth of stock for all outstanding shares and options of Principia |
| Signal Pharmaceuticals Inc. | Celgene Corp. (CELG) | 6/00 | 9/00 | $277 | Celgene issued 3.7M shares to acquire Signal (rate of 0.1257 Celgene shares per Signal share) |
| STC Technologies Inc. | Epitope Inc. (EPTO) | 5/00 | 9/00 | $260 | Companies merged to form OraSure Technologies Inc. (OSUR) to be headquartered in Bethlehem, Pa., with a focus on the oral fluid and point-of-care medical diagnostics industry; STC shareholders will receive approximately 19.3M shares of OraSure stock |
| Viral Antigens Inc. | Meridian Diagnostics Inc. (KITS) | 9/00 | 9/00 | $9 | Purchase price includes $9M in cash and earnout opportunities over the next 6 years |
| Company Acquired | Acquired By Or Merged With | Date Announced | Date Completed | Value (M) | Terms/Details |
| Atossa Healthcare Inc. | Nastech Pharmaceutical Co. Inc. (NSTK) | 8/00 | 8/00 | ND | Nastech acquired Atossa; terms ND |
| BC Research Inc. (Canada) | Immune Network Ltd. (Canada; VSE:IMM) | 8/00 | 8/00 | ND | Immune Network acquired approximately two-thirds of BC Research |
| Borealis Biosciences Inc. (Canada) | Chalon Biotech Inc. (Canada) | 8/00 | 8/00 | ND | Companies merged to form Integrative Proteomics Inc. and expect to close soon on an $8M financing |
| Schein Pharmaceutical Inc. (NYSE:SHP) | Watson Pharmaceuticals Inc. (NYSE:WPI) | 5/00 | 8/00 | $508 | Watson acquired Schein in a two-step transaction that included a cash tender and a taxable stock merger; the cash tender offer was at $19.50 per share of Schein; each Schein share was converted into $23 worth of Watson common stock; at least 24.5M shares of Schein had to be tendered under the agreement |
| Spiros Development Corp. II Inc. (SDCO) | Dura Pharmaceuticals Inc. (DURA) | 2/00 | 8/00 | $106 | Dura paid $13.25 in cash for each share of SCDCII stock, plus one five-year warrant with a calculated value of $3.22 to purchase 0.19 shares of Dura common stock exercisable at $17.94 per share |
| Xtrana Inc. | Biopool International Inc. (OTC BB:BIPL) | 5/00 | 8/00 | $9.7 | Biopool issued an aggregate of 9.4M shares of common stock in exchange for all Xtrana common and preferred stock; former shareholders of Xtrana own 50% of the company |
| Company Acquired | Acquired By Or Merged With | Date Announced | Date Completed | Value (M) | Terms/Details |
| Algos Pharmaceuticals Corp. (ALGO) | Endo Pharmaceuticals Holdings Inc. | 11/99 | 7/00 | $260 | Algos stockholders received one share of Endo stock for each share of Algos held, plus warrants to be exercised for an undisclosed price per share into Endo common stock upon FDA approval of Morphidex, if approved by 12/31/02 |
| Bio/Can Group (Canada) | Genomics One Corp. (Canada; MSE:GNX) | 7/00 | 7/00 | $3.1 | Genomics One acquired Bio/Can for $3.1M, consisting of $1M in cash, 0.14M shares of capital stock and 0.12M warrants exercisable over 24 months at $7.85 per share |
| Cambridge Discovery Chemistry (unit of Oxford Molecular Group; UK; LSE:OMG) | Millennium Pharmaceuticals Inc. (MLNM) | 7/00 | 7/00 | $53 | Millennium acquired Cambridge Discovery for $53M cash and financed the purchase through a simultaneous offering of its securities |
| Gamera Bioscience Corp. | Tecan (Switzerland; SWX:TCN) | 7/00 | 7/00 | $10 | Tecan will pay $10M, including transaction costs, to acquire the assets and intellectual property of Gamera; Tecan also hired key personnel |
| Infogen Medizinisch Genetik GmbH (Germany) | ValiGen NV (the Netherlands and U.S.) | 7/00 | 7/00 | ND | ValiGen acquired all the outstanding common stock of Infogen through a share exchange |
| NEN Life Sciences | PerkinElmer Inc. (NYSE:PKI) | 6/00 | 7/00 | $400 | PerkinElmer acquired NEN from an investor group led by Genstar Capital LLC for approximately $400M; transaction will be accounted for as a purchase |
| North Coast Clinical Laboratory Inc. | Clingenix Inc. | 7/00 | 7/00 | ND | Clingenix acquired North Coast under undisclosed terms; North Coast will join Research Services Inc. as a wholly owned subsidiary of Clingenix |
| Ontogeny Inc. and Reprogenesis Inc. | Creative BioMolecules Inc. | 2/00 | 7/00 | $434 | Companies merged to form Curis Inc., with 43 percent of shares owned by former Creative BioMolecules shareholders, 38 by Ontogeny shareholders and 19 percent by Reprogenesis shareholders |
| Solco Basel AG (Switzerland) | ICN Pharmaceuticals Inc. (NYSE:ICN) | 7/00 | 7/00 | ND | ND |
| Company Acquired | Acquired By Or Merged With | Date Announced | Date Completed | Value (M) | Terms/Details |
| ADL (Germany) | Matritech Inc. (NMPS) | 6/00 | 6/00 | $0.34M | Matritech acquired ADL for 37,153 shares of common stock, with an additional, performance-contingent payment of up to 13,700 shares to be made in 1Q:01 |
| Celtrix Pharmaceuticals Inc. (CTRX) | Insmed Pharmaceuticals Inc. (INSM) | 12/99 | 6/00 | $73 | Insmed acquired Celtrix, exchanging 1 share in a newly formed holding company for every 3.5 shares of Celtrix; former Insmed shareholders own about 59% of the merged company, while Celtrix shareholders hold about 41% |
| Cytovia Inc. | Maxim Pharmaceuticals (MAXM) | 6/00 | 6/00 | $77.2 | Maxim acquired Cytovia for approximately 1.5M shares of common stock |
| Emerald BioStructures Inc. | MediChem Research Inc. | 6/00 | 6/00 | ND | MediChem, currently in registration for an IPO, issued 84,511 shares to acquire Emerald |
| Ethrog Biotechnologies Ltd. (Israel) | Invitrogen Corp. (IVGN) | 6/00 | 6/00 | $15.2 | Invitrogen will issue 0.2M shares of common stock to acquire Ethrog |
| Genion Forschungs- | Evotec BioSystems AG (Germany; Neuer Markt:EVT) | 6/00 | 6/00 | DM5 (US$2.4) | Evotec purchased Genion in a stock transaction |
| Nanodesign Inc. | SignalGene Inc. (Canada; TSE:SGI) | 5/00 | 6/00 | C$15 (US$10.2) | SignalGene acquired Nanodesign for 5.4M common shares and 1.4M warrants, plus C$2M (US$1.35M) in cash |
| North American Vaccine Inc. (AMEX:NVX) | Baxter International Inc. (NYSE:BAX) | 11/99 | 6/00 | $380 | NAV shareholders received $6.73 per share ($6.70 in Baxter common stock and $0.03 in cash); transaction accounted for as a purchase |
| Operon Technologies Inc. | Qiagen NV (The Netherlands; Neuer Markt:QIA) | 6/00 | 6/00 | $110 | Qiagen purchased Operon with 0.6M shares of common stock and assumed options on Operon stock |
| Paracel Inc. | Celera Genomics (NYSE:CRA) | 3/00 | 6/00 | $218 | Celera acquired Paracel for 2.26M shares of common stock (worth $244.6M on 6/9/00) |
| Quay Pharmaceuticals Pty Ltd. (Australia) | Cellegy Pharmaceuticals Inc. (CLGY) | 4/00 | 6/00 | ND | Cellegy acquired Quay for stock and cash |
| Company Acquired | Acquired By Or Merged With | Date Announced | Date Completed | Value (M) | Terms/Details |
| Allegro Inc. | GenStar Therapeutics | 5/00 | 5/00 | ND | GenStar acquired technologies from Allegro for the treatment and prevention of AIDS and lentiviral gene therapy |
| The 50% stake of Althin BioPharm owned by Axcan Pharma Inc. (Canada; AXCA) | Baxter International Inc. (NYSE:BAX) | 5/00 | 5/00 | C$7.5 (US$5) | Baxter acquired Axcan's 50% interest in Althin by paying C$7.5M (US$5M) in cash at closing |
| Apoptogen Inc. (Canada) | Exogen Neurosciences Inc. (Canada) | 4/00 | 5/00 | ND | The companies merged to form Aegra Therapeutics Inc., with operations centralized in Montreal |
| Axys Advanced Technologies Inc. (unit of Axys Pharmaceuticals Inc.; AXPH) | Discovery Partners International (DPII) | 4/00 | 5/00 | $60 | Axys Pharmaceuticals Inc. spun out its combinatorial chemistry subsidiary, allowing it to merge with Discovery |
| The Liposome Co. Inc. (LIPO) | Elan Corp. plc (Ireland; NYSE:ELN) | 3/00 | 5/00 | $575 | Elan acquired all of Liposome's outstanding stock for 0.3850 of an Elan ADS and one contingent value right for each share; includes cash payment of $98M, wiht 54M contingent on approvals of Myocet and $44M contingent on the product reaching certain milestones |
| Novalon Pharmaceutical Corp. | Karo Bio (Sweden; SSE:KARO) | 3/00 | 5/00 | $107 | Karo issued 2.2M shares and option rights for about 0.09M (in total, about 20% of teh company) to Novalon shareholders; Novalon will operate as a wholly owned subsidiary of Karo with no staffing or directional changes anticipated |
| Segix Italia (Italy) | Elan Corp. plc (Ireland; NYSE:ELN) | 5/00 | 5/00 | ND | Elan acquired Segix, a marketing, sales and manufacturing company with product sales of $25M in 1999 |
| Company Acquired | Acquired By Or Merged With | Date Announced | Date Completed | Value (M) | Terms/Details |
| Mimetrix (UK; drug discovery unit of Peptide Therapeutics plc; LSE:PTH) | Medivir AB (Sweden) | 4/00 | 4/00 | ND | Medivir acquired Mimetrix for an undisclosed amount; completion of the transaction was contingent upon Medivir's raising 22M (US$35.2M) |
| Novopharm Ltd. (Canada) | Teva Pharmaceutical Industries Ltd. (Israel; TEVA) | 12/99 | 4/00 | $266 | Dan Family Holdings, the sole shareholder of Novopharm, received equity securities representing approximately 6.2% of Teva's outstanding shares |
| t. Breeders Inc. | Viacord Inc. | 4/00 | 4/00 | ND | The companies merged to form ViaCell Inc., which raised $11M from three venture capital firms upon closing of the agreement; the company will maintain two facilities |
| Company Acquired | Acquired By Or Merged With | Date Announced | Date Completed | Value (M) | Terms/Details |
| GeneScape Inc. | SignalGene (Canada; TSE:SGI) | 2/00 | 3/00 | $15.2 | SignalGene acquired GeneScape for 6.6M shares, for a total of C$22.1M (US$152M) |
| LifePlan | HIV-VAC Inc. (OTC BB:HIVC) | 3/00 | 3/00 | $0.15 | HIV-VAC Inc. became a fully reporting company via acquisition of LifePlan for 0.1M shares of stock |
| MarDx Diagnostics Inc. | Trinity Biotech plc (Ireland; TRIBY) | 3/00 | 3/00 | $4 | Trinity acquired MarDx for $4M and will locate its marketing and sales staff for North and South America in MarDx's Carlsbad, Calif., facility |
| Millennium Predictive Medicine Inc. | Millennium Pharmaceuticals Inc. (MLNM) | 3/00 | 3/00 | ND | MPMx shareholders will receive one share of new Millennium common stock in exchange for five MPMx shares, subject to adjustment for the company's recent 2-for-1 stock split |
| Mitotix Inc. | GPC AG (Germany; Neuer Markt:GPC) | 3/00 | 3/00 | ND | GPC acquired Mitotix in an all-stock transaction to create GPC Biotech AG, which will be headquartered in Munich and operate U.S. facilities in Cambridge, Mass., and Princeton, N.J. |
| Small Molecule Therapeutics Inc. | Morphochem AG (Germany) | 3/00 | 3/00 | ND | Morphochem and SMT will become a fully integrated company with SMT a wholly owned U.S. subsidiary called Morphochem Inc. |
| Strata Biosciences | GeneTrace Systems Inc. | 3/00 | 3/00 | ND | GeneTrace closed a Series B financing in conjunction with the acquisition and consolidated operations at GeneTrace's facilities in Alameda, Calif. |
| Synergy Pharmaceuticals Inc. | United Therapeutics Corp. (UTHR) | 3/00 | 3/00 | ND | As part of licensing agreement for antiviral compounds, United acquired a 15% stake in Synergy with an option to acquire the remainder |
| Tyrogene Biotechnologies Inc. | Kinetek Pharmaceuticals Inc. | 3/00 | 3/00 | ND | Kinetek acquired Tyrogene and its assets and expertise for the development of protein tyrosine phosphates |
| Company Acquired | Acquired By Or Merged With | Date Announced | Date Completed | Value (M) | Terms/Details |
| Advanced Cell Technology Inc. | ACT Group Inc. | 2/00 | 2/00 | ND | ACT acquired a majorty of Avian Farm's interest in Advanced Cell, as well as stakes in two agbiotech companies (CIMA Biotechnology Inc. and Cyagra LLC) |
| American Advanced Organics Inc. | Albany Molecular Research Inc. (AMRI) | 2/00 | 2/00 | $2.3 | Albany acquired AAO for $2.3M in cash and stock and will pay up to $0.8M in addition based on AAO's financial performance in 2000 and 2001 |
| Cancer Diagnostic Inc. | Lexon Inc. | 2/00 | 2/00 | $0.2M | Lexon acquired Cancer Diagnostic for $0.2M in cash and notes, made in lieu of Lexon's original plan to merge by issuing 0.5M shares to Cancer Diagnostic's owners |
| Cobra Therapeutics Ltd. (UK) | ML Laboratories plc (UK) | 2/00 | 2/00 | 8 (US$12.7) | Cobra shareholder ML Laboratories acquired the company in an all-share deal valuing Cobra at 8M (US$12.7M); in addition, ML will pay up to 12M (US19.2M) in milestones; Cobra's facilities will be retained |
| DNA Sciences | Genetic Vectors Inc. | 10/99 | 2/00 | $2.5 | Genetic Vectors acquired DNA Sciences for 0.45M common shares (2/1) |
| Genetic MicroSystems Inc. | Affymetrix Inc. (AFFX) | 9/99 | 2/00 | $100 | Affymetrix acquired Genetic MicroSystems by issuing approximately 1M shares of common stock for all outstanding GMS shares |
| Kimeragen Inc. | ValiGene SA (France) | 2/00 | 2/00 | ND | Under merger-of-equals transaction, companies created ValiGen, with scientific operations in both Paris and Newtown, Pa., and an agricultural division in San Diego |
| Opticon Inc. | Immune Response Inc. (IMNR) | 1/00 | 2/00 | $3 | Immune Response acquired Opticon and is now operating through its wholly owned subsidiary, Opticon Medical Inc. |
| Pharmazyme (division of Immune Complex Corp.; IMNX) | PPD Discovery (unit of PPD Inc.; PPDI) | 2/00 | 2/00 | ND | PPD acquired the assets of Pharmazyme, which develops, makes and markets drug metabolism reagent products and services |
| Research Genetics Inc. | Invitrogen Corp. (IVGN) | 6/99 | 2/00 | $220.8 | Invitrogen acquired Research Genetics for 3.2M Invitrogen sharese |
| Synopsys Scientific Systems Ltd. | Pharmacopeia Inc. (PCOP) | 2/00 | 2/00 | $25 | Pharmacopeia acquired all of Synopsys' outstanding stock in a transaction valued at approximately $25M, consisting primarily of cash |
| Vysis Sarl (France) | Applied Genetic Services Ltd. | 2/00 | 2/00 | $1.2 | Vysis sold its wholly owned French subsidiary, Vysis Sarl, for $1.2M; in conjunction with the sale, AGS was appointed Vysis' exclusive French distributor for several product lines |
| Company Acquired | Acquired By Or Merged With | Date Announced | Date Completed | Value (M) | Terms/Details |
| BioNexus Genomics Inc. | Ashni Nutraceuticals Inc. | 1/00 | 1/00 | ND | Terms ND |
| Cambridge Drug Discovery Ltd. (UK) | Cambridge Genetics Ltd. (UK) | 1/00 | 1/00 | 8.25E (US$13.2) | The merger was accomplished through a stock-for-stock exchange; CGL also paid Oxford Molecular Group plc (LSE:OMG) 1.65M (US$2.64M) for its 20% stake |
| Discovery Technologies Ltd. | Discovery Partners International (DPII) | 6/99 | 1/00 | ND | Discovery Technologies became a wholly owned subsidiary of Discovery Partners, retaining its headquarters in Switzerland |
| Heaven's Door Corp. | Procept Inc. | 11/99 | 1/00 | $67.2 | Procept issued 10.92M shares of common stock to Heaven's Door shareholders in exchange for 65% ownership of the new firm, HeavenlyDoor.com (HVDC); |
| Medeva plc (UK) | Celltech Chiroscience (UK; NYSE:CLL) | 11/99 | 1/00 | 563 (US$912) | Celltech acquired Medeva, offering 34 new shares for every 100 Medeva shares; Celltech shareholders now hold 56% of the combined company, which is called Celltech Group plc, with Medeva investors owning 44% |
| Shanghai Genecore Biotechnologies Co. Ltd. (China) | Celera Genomics (NYSE:CRA) | 1/00 | 1/00 | ND | Celera acquired 47.5% of the equity in Shanghai, a stake formerly held by Axys Pharmaceuticals Inc. (AXPH); Celera's sister company PE Biosystems (NYSE: PEB) also owns 47.5% interest, giving parent firm PE Corp. a 95% stake |